Form 4: EcoR1 Capital, LLC Sells Shares of Tango Therapeutics, Inc.

EcoR1 Capital, LLC, along with related entities, reports the sale of Tango Therapeutics, Inc. (TNGX) common stock across multiple transactions.

Summary

• EcoR1 Capital, LLC, Oleg Nodelman, and EcoR1 Capital Fund Qualified, L.P. jointly filed a Form 4 regarding transactions in Tango Therapeutics, Inc. (TNGX) common stock.
• On November 6, 2024, Qualified Fund sold 1,406,529 shares at $3.2759 per share.
• On November 7, 2024, Qualified Fund sold 58,647 shares at $3.2914 per share and 1,075,794 shares at $2.9171 per share.
• Following these transactions, Qualified Fund holds 10,022,411 shares of Tango Therapeutics, Inc.'s common stock.
• The filers disclaim beneficial ownership except to the extent of their respective pecuniary interests.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative as a major shareholder is reducing their position in the company. This could indicate a lack of confidence or a need to rebalance their portfolio.

Negatives

• EcoR1 Capital, LLC and related entities reduced their holdings in Tango Therapeutics, Inc.

Risks

• Continued selling pressure from major shareholders like EcoR1 could negatively impact TNGX's stock price.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders or major shareholders of a publicly traded company buy or sell shares; these filings are closely watched by investors for signals about the company's prospects and insider sentiment.

Stakeholder Impact

• Shareholders may react negatively to the news of a major shareholder selling off shares.
• The stock price of Tango Therapeutics, Inc. (TNGX) could be negatively impacted by these sales.

Key Dates